Board approves three investment plans Spike Pharmaceuticals expands again
Release time:
2020-08-14
News from our newspaper 8# April 3 , the group company held the fifth meeting of the 10th board of directors, deliberated and passed three proposals on the capital increase of Shanghai Beika by Jianfeng Pharmaceutical, the acquisition of Anhui Zhongwang Pharmaceutical Company by subsidiary Shanghai Beika, and the annual production of 20 .8 billion solid preparations in Jinxi Production Base of Jianfeng Pharmaceutical.
The three investment plans approved by the board of directors this time are important measures to further strengthen the company's pharmaceutical business segment in accordance with the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development. Among them, Jianfeng Pharmaceutical Co., Ltd. invested ,000 yuan to increase the capital of Shanghai North Card. After the capital increase is completed, Jianfeng Pharmaceutical Co., Ltd. will account for 61.48% of Shanghai North Card. Shanghai North Card will invest 2062 yuan to acquire Anhui Zhongwang 100% equity.
In 1 this year, Jianfeng Pharmaceutical signed an agreement with relevant parties to invest in Shanghai Beika by way of equity acquisition and capital increase, and completed the investment in 5 . Shanghai Beika and its subsidiary Anhui Xinbeika Company have become the controlling subsidiary of Jianfeng Pharmaceutical. Anhui Zhongwang, which Shanghai Beika acquired this time, is also located in Dongzhi Xiangyu Chemical Industrial Park, Chizhou City, Anhui Province. It is a pharmaceutical intermediate manufacturing enterprise integrating R & D, production and sales, focusing on the R & D, production and sales of characteristic medicines, intermediates, new materials and other fine chemicals. Anhui Zhongwang's main products are oxyfluorocarbons, oxyfluorocarbons, levooxyfluorocarbons, and levooxyfluorocarbons, which have passed on-site audits by well-known domestic pharmaceutical companies. L-fluorocycloester passed an on-site audit of a pharmaceutical company in India. 2017 12 accepted the on-site audit of oxyfluorocarboxylic acid process verification by U.S. pharmaceutical companies, and Zhongwang has been registered as a supplier of oxyfluorocarboxylic acid starting materials in U.S. document DMF . After the completion of the acquisition, the company will make use of Anhui Zhongwang's factory buildings and construction land to plan the construction of pharmaceutical intermediates and API projects, so as to provide a strong guarantee for Jianfeng Pharmaceutical to establish a chemical API base.
At the same time, Jianfeng Pharmaceutical will also invest 50146 yuan to set up a new factory on the north side of the existing factory area of Jianfeng Pharmaceutical in Jinxi District of Jinhua Economic Development Zone to build a preparation manufacturing platform that meets the requirements of GMP in Europe and America. (remaining fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page